Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCAT1 | P54687 | 9/20 | 0.41 |
| ▸ | BCAT2 | O15382 | 8/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.35 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL32677867 | 0.83 | BCAT1 (0.44) | BCAT1BCAT2ALDH1A1SMN1; SMN2CYP2C9 | |
| SCHEMBL28425956 | 0.74 | BCAT2 (0.36) | BCAT1BCAT2 | |
| SCHEMBL28425958 | 0.73 | BCAT1 (0.36) | BCAT1BCAT2SMN1; SMN2TSHR | |
| SCHEMBL21653845 | 0.73 | BCAT1 (0.38) | BCAT1BCAT2ALDH1A1SMN1; SMN2HSD17B10 | |
| SCHEMBL2838083 | 0.73 | BCAT1 (0.43) | BCAT1BCAT2SMN1; SMN2 | |
| SCHEMBL1573292 | 0.73 | BCAT1 (0.43) | BCAT1BCAT2ALDH1A1SMN1; SMN2CYP2C9 | |
| SCHEMBL2840843 | 0.72 | BCAT1 (0.42) | BCAT1BCAT2ALDH1A1SMN1; SMN2CYP2C9 | |
| SCHEMBL2832383 | 0.72 | BCAT1 (0.43) | BCAT1BCAT2SMN1; SMN2 | |
| SCHEMBL9423250 | 0.70 | BCAT1 (0.48) | BCAT1BCAT2KMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL9274567 | 0.69 | TDP1 (0.50) | BCAT1BCAT2ALDH1A1SMN1; SMN2CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12503462-B2 | Method for preparing isoxazoline-containing uracil compound through methylation | SHENYANG SINOCHEM AGROCHEMICALS R&D CO., LTD. (CN) | 2025-12-23 | — | — | US | disclosed |
| EP-3858829-B1 | METHOD FOR PREPARING ISOXAZOLINE-CONTAINING URACIL COMPOUND BY METHYLATION | SHENYANG SINOCHEM AGROCHEMICALS R & D CO LTD (CN) | 2024-05-01 | — | — | EP | disclosed |
| CN-110964001-B | Method for preparing isoxazoline-containing uracil compound through methylation | 沈阳中化农药化工研发有限公司 | 2022-07-22 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12503462-B2 | Method for preparing isoxazoline-containing uracil compound through methylation | UNG, DNMT1, NUDT1 | BCAT1 659/4885BCAT2 684/4885KMT2A 234/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.